Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19. The study purpose is to evaluate the safety and efficacy of four IV infusions of either placebo or HB-adMSCs in subjects with COVID-19.
Description: change from baseline in interleukin-6
Measure: Interleukin-6 Time: screening, day 0, 7, 10Description: Change from baseline in C Reactive protein
Measure: C Reactive protein Time: screening, day 0, 7, 10Description: change from baseline oxygenation (%)
Measure: Oxygenation Time: screening, day 0, 7, 10Description: change from baseline in TNF alpha
Measure: TNF alpha Time: screening, day 0, 7, 10Description: change from baseline level of IL-10 in the blood (pg/mL)
Measure: IL-10 Time: screening, day 0, 7. 10Description: Time to return to room air
Measure: Return to room air (RTRA) Time: Day 0, 3, 7, 10, 28Description: Monitoring for changes in qt interval
Measure: EKG qt interval Time: screening, day 0, 3, 7, 10Description: change from baseline in leukocyte differential
Measure: Leukocyte differential Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of glucose in the blood (mg/dL)
Measure: Glucose Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of calcium in the blood (mg/dL)
Measure: Calcium Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of albumin in the blood (g/dL)
Measure: Albumin Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of total protein in the blood (g/dL)
Measure: Total protein Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of sodium in the blood (mol/L)
Measure: Sodium Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of total carbon dioxide in the blood (mmol/L)
Measure: Total carbon dioxide Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of potassium in the blood (mmol/L)
Measure: Potassium Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of chloride in the blood (mmol/L)
Measure: Chloride Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of BUN in the blood (mg/dL)
Measure: BUN Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of creatinine in the blood (mg/dL)
Measure: Creatinine Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)
Measure: Alkaline phosphatase Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)
Measure: Alanine aminotransferase Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of total bilirubin in the blood (mg/dL)
Measure: Total bilirubin Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of white blood cells in the blood (x10^3/uL)
Measure: White blood cells Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of red blood cells in the blood (x10^6/uL)
Measure: Red blood cells Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of hemoglobin in the blood (g/dL)
Measure: Hemoglobin Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of hematocrit in the blood (%)
Measure: Hematocrit Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of mean corpuscular volume in the blood (fL)
Measure: Mean corpuscular volume Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of mean corpuscular hemoglobin in the blood (pg)
Measure: Mean corpuscular hemoglobin Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of mean corpuscular hemoglobin concentration in the blood (g/dL)
Measure: Mean corpuscular hemoglobin concentration Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of red cell distribution width in the blood (%)
Measure: Red cell distribution width Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of neutrophils in the blood (%)
Measure: Neutrophils Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of lymphocytes in the blood (%)
Measure: Lymphs Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of monocytes in the blood (%)
Measure: Monocytes Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of eosinophils in the blood (%)
Measure: Eosinophils Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of basophils in the blood (%)
Measure: Basophils Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of absolute neutrophils in the blood (x10^3/uL)
Measure: Absolute neutrophils Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of absolute lymphocytes in the blood (x10^3/uL)
Measure: Absolute lymphs Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of absolute monocytes in the blood (x10^3/uL)
Measure: Absolute monocytes Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of absolute eosinophils in the blood (x10^3/uL)
Measure: Absolute eosinophils Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of absolute basophils in the blood (x10^3/uL)
Measure: Absolute basophils Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of immature granulocytes in the blood (x10^3/uL)
Measure: Immature granulocytes Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of platelets in the blood (x10^3/uL)
Measure: Platelets Time: screening, day 0, 7, 10Description: clinical lab evaluation of time for blood to coagulate (seconds)
Measure: Prothrombin time Time: screening, day 0, 7, 10Description: clinical lab evaluation of international normalized ratio of blood coagulation (no unit)
Measure: INR Time: screening, day 0, 7, 10Description: clinical lab evaluation of percentage of cells CD3- and CD54+ (%)
Measure: NK cell surface antigen (CD3-CD54+) Time: screening, day 0, 7, 10Description: clinical lab evaluation of ratio of CD4+ cells to CD8+ cells (no unit)
Measure: CD4+/CD8+ ratio Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of myoglobin in the blood (ng/mL)
Measure: Myoglobin Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of myoglobin in the blood (ng/mL)
Measure: Troponin Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of creatinine kinase in the blood (U/L)
Measure: Creatinine kinase MB Time: screening, day 0, 7, 10Description: clinical lab evaluation of level of serum ferritin in the blood (ng/mL)
Measure: Serum ferritin Time: screening, day 0, 7, 10Description: incidence of adverse events
Measure: Adverse events Time: screening through day 28Description: change from baseline in ordinal scale score; scale of 1-7; a score of 1 indicates death and 7 indicates subject is not hospitalized and has no limitations on activities.
Measure: 7-point ordinal scale Time: screening, day 0, 3, 7, 10, 28Description: change from baseline in D-dimer
Measure: D-dimer Time: screening, day 0, 7, 10Description: change from baseline chest x-ray result
Measure: Chest X-ray Time: Day 0, Day 28Description: change from baseline CT scan result
Measure: CT scan Time: Day 0, Day 28Description: time to achieve negative PCR test results
Measure: PCR test for SARS-CoV-2 Time: day 0, 3, 7, 10Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports